Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)

Masahiro Hiasa, Masahiro Abe, Ayako Nakano, Asuka Oda, Hiroe Amou, Shinsuke Kido, Kyoko Takeuchi, Kumiko Kagawa, Kenichiro Yata, Toshihiro Hashimoto, Shuji Ozaki, Kenzo Asaoka, Eiji Tanaka, Keiji Moriyama, Toshio Matsumoto

Blood (2009) 114 (20): 4517–4526.

https://doi.org/10.1182/blood-2009-04-215020

Published: 2009

Includes: Supplemental data

Journal Articles

The Serine/Threonine Kinase Pim-2 Is a Novel Anti-Apoptotic Mediator in Myeloma Cells.

Jin Asano, MD, Masahiro Abe, MD, Shiro Fujii, MD, Osamu Tanaka, MD, Ai Mihara, MD, Shingen Nakamura, MD, Kazuhiro Miki, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, Kenichiro Yata, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Masahiro Hiasa, DDS, Toshio Matsumoto, MD

Blood (2007) 110 (11): 243.

https://doi.org/10.1182/blood.V110.11.243.243

Published: 2007

Journal Articles

Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.

Kumiko Kagawa, MD, Masahiro Abe, MD, Shiro Fujii, MD, Osamu Tanaka, MD, Ai Mihara, MD, Shingen Nakamura, MD, Kazuhiro Miki, MD, Jin Asano, MD, Kyoko Takeuchi, MD, Kenichiro Yata, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Masahiro Hiasa, DDS, Toshio Matsumoto, MD

Blood (2007) 110 (11): 244.

https://doi.org/10.1182/blood.V110.11.244.244

Published: 2007

Journal Articles

Combination of a Spicamycin Analogue KRN5500 and Chemotherapeutic Agents Synergistically Enhances Their Cytotoxicity in Human Myeloma Cells.

Hirokazu Miki, MD, Shuji Ozaki, MD, Osamu Tanaka, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ai Mihara, MD, Kumiko Kagawa, MD, Jin Asano, MD, Kyoko Takeuchi, MD, Kenichiro Yata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Toshio Matsumoto, MD

Blood (2007) 110 (11): 4783.

https://doi.org/10.1182/blood.V110.11.4783.4783

Published: 2007

Journal Articles

SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.

Kyoko Takeuchi, MD, Masahiro Abe, MD, Asuka Oda, MT, Hiroe Amou, MT, Masahiro Hiasa, DDS, Jin Asano, MD, Kenichi Kitazoe, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Shinsuke Kido, PhD, Daisuke Inoue, MD, Toshio Matsumoto, MD

Blood (2006) 108 (11): 3479.

https://doi.org/10.1182/blood.V108.11.3479.3479

Published: 2006

Journal Articles

Emerging of Valproic Acid as an Anti-Myeloma Agent.

Kenichi Kitazoe, MD, Masahiro Abe, MD, Masahito Choraku, MD, Kumiko Kagawa, MD, Jin Asano, MD, Kyoko Takeuchi, MD, Masahiro Hiasa, DDS, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Asuka Oda, MT, Hiroe Amou, MT, Toshio Matsumoto, MD

Blood (2006) 108 (11): 3482.

https://doi.org/10.1182/blood.V108.11.3482.3482

Published: 2006

Journal Articles

Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).

Shuji Ozaki, Takafumi Tomura, Etsuko Sekimoto, Yoichi Tanaka, Kenichi Kitazoe, Jin Asano, Toshihiro Hashimoto, Masahiro Abe, Takayuki Furuta, Tomoyuki Tahara, Isao Ishida, Shiro Kataoka, Toshio Matsumoto

Blood (2005) 106 (11): 3388.

https://doi.org/10.1182/blood.V106.11.3388.3388

Published: 2005

Journal Articles

Angiogenesis and Osteoclastogenesis Are Mutually Stimulated in Myeloma: A Role for VEGF and Osteopontin.

Yoichi Tanaka, Masahiro Abe, Masahiro Hiasa, Toshihiro Hashimoto, Shinsuke Kido, Daisuke Inoue, Shuji Ozaki, Keiji Moriyama, Toshio Matsumoto

Blood (2005) 106 (11): 2500.

https://doi.org/10.1182/blood.V106.11.2500.2500

Published: 2005

Journal Articles

Induction of HM1.24 peptide–specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma

Ali Jalili, Shuji Ozaki, Tomoko Hara, Hironobu Shibata, Toshihiro Hashimoto, Masahiro Abe, Yasuhiko Nishioka, Toshio Matsumoto

Blood (2005) 106 (10): 3538–3545.

https://doi.org/10.1182/blood-2005-04-1438

Published: 2005

Journal Articles

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2

Takashi Oshima, Masahiro Abe, Jin Asano, Tomoko Hara, Kenichi Kitazoe, Etsuko Sekimoto, Yoichi Tanaka, Hironobu Shibata, Toshihiro Hashimoto, Shuji Ozaki, Shinsuke Kido, Daisuke Inoue, Toshio Matsumoto

Blood (2005) 106 (9): 3160–3165.

https://doi.org/10.1182/blood-2004-12-4940

Published: 2005

Journal Articles

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Takashi Oshima, MD, Masahiro Abe, MD, Jin Asano, MD, Tomoko Hara, MD, Kenichi Kitazoe, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Shinsuke Kido, MD, Daisuke Inoue, MD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 2356.

https://doi.org/10.1182/blood.V104.11.2356.2356

Published: 2004

Journal Articles

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Shuji Ozaki, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Takashi Ohshima, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Kazuhiro Motoki, PhD, Isao Ishida, PhD, Shiro Kataoka, PhD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 3366.

https://doi.org/10.1182/blood.V104.11.3366.3366

Published: 2004

Journal Articles

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Ali Jalili, Shuji Ozaki, MD, Tomoko Hara, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Takashi Ohshima, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Yasuhiko Nishioka, MD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 1487.

https://doi.org/10.1182/blood.V104.11.1487.1487

Published: 2004

Journal Articles

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

Masahiro Abe, Kenji Hiura, Javier Wilde, Atsushi Shioyasono, Keiji Moriyama, Toshihiro Hashimoto, Shinsuke Kido, Takashi Oshima, Hironobu Shibata, Shuji Ozaki, Daisuke Inoue, Toshio Matsumoto

Blood (2004) 104 (8): 2484–2491.

https://doi.org/10.1182/blood-2003-11-3839

Published: 2004

Journal Articles

Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

Masahiro Abe, Kenji Hiura, Javier Wilde, Keiji Moriyama, Toshihiro Hashimoto, Shuji Ozaki, Shingo Wakatsuki, Masaaki Kosaka, Shinsuke Kido, Daisuke Inoue, Toshio Matsumoto

Blood (2002) 100 (6): 2195–2202.

https://doi.org/10.1182/blood.V100.6.2195

Published: 2002

NARROW

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)

The Serine/Threonine Kinase Pim-2 Is a Novel Anti-Apoptotic Mediator in Myeloma Cells.

Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.

Combination of a Spicamycin Analogue KRN5500 and Chemotherapeutic Agents Synergistically Enhances Their Cytotoxicity in Human Myeloma Cells.

SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.

Emerging of Valproic Acid as an Anti-Myeloma Agent.

Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).

Angiogenesis and Osteoclastogenesis Are Mutually Stimulated in Myeloma: A Role for VEGF and Osteopontin.

Induction of HM1.24 peptide–specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only